{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:11:35Z","timestamp":1778037095644,"version":"3.51.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute for Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA053232"],"award-info":[{"award-number":["1R01DA053232"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To mitigate pandemic-related disruptions to addiction treatment, US federal and state governments made significant changes to policies regulating treatment delivery. State health agencies played a key role in implementing these policies, giving agency leaders a distinct vantage point on the feasibility and implications of post-pandemic policy sustainment. We interviewed 46 state health agency and other leaders responsible for implementing COVID-19 addiction treatment policies across 8 states with the highest COVID-19 death rate in their census region. Semi-structured interviews were conducted from April through October 2022. Transcripts were analyzed using summative content analysis to characterize policies that interviewees perceived would, if sustained, benefit addiction treatment delivery long-term. State policies were then characterized through legal database queries, internet searches, and analysis of existing policy databases. State leaders viewed multiple pandemic-era policies as useful for expanding addiction treatment access post-pandemic, including relaxing restrictions for telehealth, particularly for buprenorphine induction and audio-only treatment; take-home methadone allowances; mobile methadone clinics; and out-of-state licensing flexibilities. All states adopted at least 1 of these policies during the pandemic. Future research should evaluate these policies outside of the acute COVID-19 pandemic context.<\/jats:p>","DOI":"10.1093\/haschl\/qxae007","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T13:38:45Z","timestamp":1706535525000},"source":"Crossref","is-referenced-by-count":4,"title":["Navigating addiction treatment during COVID-19: policy insights from state health leaders"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1373-1809","authenticated-orcid":false,"given":"Sarah A","family":"White","sequence":"first","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3524-3454","authenticated-orcid":false,"given":"Alexander D","family":"McCourt","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4790-4731","authenticated-orcid":false,"given":"Kayla N","family":"Tormohlen","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medicine , New York, NY 10065 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7518-6220","authenticated-orcid":false,"given":"Jiani","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medicine , New York, NY 10065 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma E","family":"McGinty","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medicine , New York, NY 10065 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"issue":"7","key":"2024020911191001800_qxae007-B1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","article-title":"COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January\u2012July 2020","volume":"111","author":"Friedman","year":"2021","journal-title":"Am J Public Health"},{"issue":"4","key":"2024020911191001800_qxae007-B2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic","volume":"79","author":"Friedman","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2024020911191001800_qxae007-B3","doi-asserted-by":"crossref","first-page":"108180","DOI":"10.1016\/j.jsat.2020.108180","article-title":"COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns","volume":"121","author":"Mellis","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"2024020911191001800_qxae007-B4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/appi.ps.202000565","article-title":"How physician workforce shortages are hampering the response to the opioid crisis","volume":"73","author":"McNeely","year":"2022","journal-title":"Psychiatr Serv"},{"issue":"3","key":"2024020911191001800_qxae007-B5","doi-asserted-by":"crossref","first-page":"e220093","DOI":"10.1001\/jamahealthforum.2022.0093","article-title":"Trends in engagement with opioid use disorder treatment among Medicaid beneficiaries during the COVID-19 pandemic","volume":"3","author":"Tilhou","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"24","key":"2024020911191001800_qxae007-B6","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1001\/jama.2020.21231","article-title":"Psychological distress and COVID-19-related stressors reported in a longitudinal cohort of US adults in April and July 2020","volume":"324","author":"McGinty","year":"2020","journal-title":"JAMA"},{"key":"2024020911191001800_qxae007-B7","author":"National Institute on Drug Abuse"},{"key":"2024020911191001800_qxae007-B8","author":"National Center for Health Statistics"},{"issue":"16","key":"2024020911191001800_qxae007-B9","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/jama.2022.17613","article-title":"Employment in office-based and intensive behavioral health settings in the US, 2016-2021","volume":"328","author":"Eisenberg","year":"2022","journal-title":"JAMA"},{"key":"2024020911191001800_qxae007-B10","doi-asserted-by":"crossref","first-page":"103537","DOI":"10.1016\/j.drugpo.2021.103537","article-title":"Experiences with substance use disorder treatment during the COVID-19 pandemic: findings from a multistate survey","volume":"101","author":"Saloner","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2024020911191001800_qxae007-B11","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences Engineering Medicine","year":"2019"},{"key":"2024020911191001800_qxae007-B12","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2024020911191001800_qxae007-B13","author":"Prescription Drug Abuse Policy System (PDAPS)"},{"issue":"3","key":"2024020911191001800_qxae007-B14","doi-asserted-by":"crossref","first-page":"e230071","DOI":"10.1001\/jamahealthforum.2023.0071","article-title":"State policies could impede new efforts to increase access to medications for opioid use disorder","volume":"4","author":"Barsky","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"3","key":"2024020911191001800_qxae007-B15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2024020911191001800_qxae007-B16","doi-asserted-by":"crossref","first-page":"108074","DOI":"10.1016\/j.jsat.2020.108074","article-title":"Lessons from COVID 19: are we finally ready to make opioid treatment accessible?","volume":"117","author":"Krawczyk","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"2024020911191001800_qxae007-B17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.annemergmed.2021.03.023","article-title":"Improve access to care for opioid use disorder: a call to eliminate the X-waiver requirement now","volume":"78","author":"D\u2019Onofrio","year":"2021","journal-title":"Ann Emerg Med"},{"issue":"1","key":"2024020911191001800_qxae007-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1803982","article-title":"Methadone in primary care\u2014one small step for congress, one giant leap for addiction treatment","volume":"379","author":"Samet","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2024020911191001800_qxae007-B19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/08897077.2021.1903659","article-title":"It will end in tiers: a strategy to include \u201cdabblers\u201d in the buprenorphine workforce after the X-waiver","volume":"42","author":"Saloner","year":"2021","journal-title":"Subst Abus"},{"issue":"1","key":"2024020911191001800_qxae007-B20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: the influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"2024020911191001800_qxae007-B21","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"2024020911191001800_qxae007-B22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/07853890.2023.2171107","article-title":"Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019","volume":"55","author":"Andraka-Christou","year":"2023","journal-title":"Ann Med"},{"issue":"2","key":"2024020911191001800_qxae007-B23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","article-title":"Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment","volume":"41","author":"Green","year":"2020","journal-title":"Subst Abus"},{"key":"2024020911191001800_qxae007-B24","doi-asserted-by":"crossref","first-page":"108263","DOI":"10.1016\/j.jsat.2020.108263","article-title":"Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder","volume":"123","author":"Stringer","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"2024020911191001800_qxae007-B25","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/ADM.0000000000000685","article-title":"Innovation during COVID-19: improving addiction treatment access","volume":"14","author":"Samuels","year":"2020","journal-title":"J Addict Med"},{"key":"2024020911191001800_qxae007-B26","first-page":"120","volume-title":"COVID-19 Policy Playbook: Legal Recommendations for a Safer, More Equitable Future","author":"Davis","year":"2021"},{"key":"2024020911191001800_qxae007-B27","author":"Manatt on Health"},{"issue":"5","key":"2024020911191001800_qxae007-B28","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/1475-6773.14173","article-title":"State Medicaid and private telemedicine coverage requirements and telemedicine use, 2013-2019","volume":"58","author":"Lipton","year":"2023","journal-title":"Health Serv Res"},{"key":"2024020911191001800_qxae007-B29","author":"Centers for Disease Control and Prevention"},{"key":"2024020911191001800_qxae007-B30","author":"Kaiser Family Foundation"},{"key":"2024020911191001800_qxae007-B31","author":"National Academy for State Health Policy"},{"key":"2024020911191001800_qxae007-B32","author":"Drug Enforcement Administration"},{"key":"2024020911191001800_qxae007-B33","author":"El-Sabawi"},{"issue":"9","key":"2024020911191001800_qxae007-B34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.37765\/ajmc.2022.89221","article-title":"Physician response to COVID-19-driven telehealth flexibility for opioid use disorder","volume":"28","author":"Beetham","year":"2022","journal-title":"Am J Manag Care"},{"issue":"9","key":"2024020911191001800_qxae007-B35","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s11606-023-08165-9","article-title":"Long-term prospects for telemedicine in opioid use disorder (OUD) treatment: results from a longitudinal survey of OUD clinicians","volume":"38","author":"Huskamp","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2024020911191001800_qxae007-B36","doi-asserted-by":"crossref","first-page":"108514","DOI":"10.1016\/j.jsat.2021.108514","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms","volume":"132","author":"Treitler","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"23","key":"2024020911191001800_qxae007-B37","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1001\/jama.2020.21512","article-title":"Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic","volume":"324","author":"Huskamp","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2024020911191001800_qxae007-B38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1176\/appi.ps.20230102","article-title":"Trends in opioid use disorder outpatient treatment and telehealth utilization before and during the COVID-19 pandemic","volume":"75","author":"Tormohlen","year":"2023","journal-title":"Psychiatr Serv"},{"issue":"10","key":"2024020911191001800_qxae007-B39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2024020911191001800_qxae007-B40","doi-asserted-by":"crossref","first-page":"e2252381","DOI":"10.1001\/jamanetworkopen.2022.52381","article-title":"Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic","volume":"6","author":"Hailu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024020911191001800_qxae007-B41","author":"Desai"},{"key":"2024020911191001800_qxae007-B42","author":"D\u2019Arrigo"},{"key":"2024020911191001800_qxae007-B43","author":"American Society of Addiction Medicine"},{"key":"2024020911191001800_qxae007-B44","author":"Center for Connected Health Policy"},{"key":"2024020911191001800_qxae007-B45","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2024020911191001800_qxae007-B46","author":"Drug Enforcement Administration"},{"key":"2024020911191001800_qxae007-B47","article-title":"New methadone treatment regulations should be complemented by payment and financing reform","author":"Bowser","journal-title":"Health Affairs Forefront"},{"issue":"3","key":"2024020911191001800_qxae007-B48","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy","volume":"8","author":"Krawczyk","year":"2023","journal-title":"Lancet Public Health"},{"issue":"1","key":"2024020911191001800_qxae007-B49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13011-021-00395-6","article-title":"The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review","volume":"16","author":"Alexander","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"11","key":"2024020911191001800_qxae007-B50","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamapsychiatry.2020.1511","article-title":"Methadone for opioid use disorder-decades of effectiveness but still miles away in the US","volume":"77","author":"Joudrey","year":"2020","journal-title":"JAMA Psychiatry"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxae007\/56446264\/qxae007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/2\/qxae007\/56641377\/qxae007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/2\/qxae007\/56641377\/qxae007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:19:33Z","timestamp":1707477573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxae007\/7591172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxae007","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,29]]},"article-number":"qxae007"}}